市场调查报告书
商品编码
1150171
心臟安全服务全球市场规模、份额和行业趋势分析报告:按类型、最终用户、服务类型和地区划分的展望和预测,2022-2028 年Global Cardiac Safety Services Market Size, Share & Industry Trends Analysis Report By Type, By End User, By Type of Service, By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,全球心臟安全服务市场规模预计将达到 11 亿美元,预测期内的复合年增长率为 11.1%。
心血管系统的所有组成部分,包括心臟、血管和血液成分,都受到心血管安全责任的影响,包括心血管和非心血管药物。心血管副作用可以是功能性或结构性的(例如,组织病理学),并且可以在急性或慢性治疗后发生。
在当今世界,公众监督日益严格,经营成本不断上升,监管资源有限,因此比以往任何时候都更需要有效和安全的药物开发。心血管疾病 (CVD) 每年有 1790 万人死亡,是全世界最常见的死亡原因。脑血管病、冠心病、风湿性心脏病都属于称为CVD的心臟和血管疾病范畴。
COVID-19 影响分析
这促使製药和健康保险行业做出必要的改变,以更好地为他们服务。此外,医学的进步需要许多专门研究心臟健康的研究机构和组织的参与。与冠状病毒相关的灾难已导致许多患有既往疾病的患者死亡,并影响了心臟安全服务。 COVID-19的蓬勃市场发展对整个心臟安全服务市场产生了积极影响。
市场增长因素
生物仿製药和生物製品研究的增加
许多公司都在大力投资生物製剂和生物仿製药的研发。在探索阶段,多□、蛋白质和单克隆抗体等生物製剂占治疗候选药物的一半以上。製药和生物製药公司正在大力投资研发新的生物製品,以开发或在研产品。此外,生物仿製药是专利生物製剂的仿製药,不受严格监管,因此价格较低。
Ech 露背服务在普通人群中的流行度很高
心电图动态心电图的流行很大程度上是由于老年人口的增加和心血管疾病发病率的增加。根据 Health System Tracker 发布的数据,心脏病是美国的主要死因。由于这些原因,需要能够即时检测心跳并时刻监控心跳的设备。在过去几年中,医疗保健系统已采用心电图监测设备来检查异常心臟活动。
市场製约因素
临床试验缺乏合格人员
製药、生物技术和医疗器械研发外包行业瞬息万变。需要高技能的专业人员提供高质量的服务,遵守可接受的实验室程序,并跟上医疗器械和药物研发技术和方法的进步。 CRO 与生物技术、製药和医疗器械公司以及研究和学术机构竞争训练有素、经验丰富的科学家,因此难以吸引和留住高技能人才。
按类型划分的前景
心臟安全服务市场按类型分为集成式和独立式。综合细分市场在 2021 年的收入份额最高的心臟安全服务市场占据主导地位。这些最先进的核心实验室服务提供全方位的心臟安全服务,包括成像、TQT 和 QT 曲线测试。为了支持对心率和节律的实时评估,我们还查看脱靶心血管债务并在持照护士的监督下进行现场多通道遥测。
按服务类型划分的前景
心臟安全服务市场按服务类型分为 ECG/Holter 测量、血压测量、心血管成像、QT 测试和其他服务。 ECG/Holter 测量部分将在 2021 年见证心臟安全服务市场中最大的收入份额。智能手錶和其他个人电子产品提供心电图监测。一种称为 Holter 监视器的小型便携式设备用于捕捉您的心跳。它用于识别和评估异常心跳(心律失常)的可能性。
最终用户视角
心臟安全服务市场根据最终用户细分为製药/生物製药公司和合同研究组织。合同研究机构部门在 2021 年提高了心臟安全服务市场的可观收入份额。临床试验由合同研究组织 (CRO) 为製药、医疗器械和生物技术公司以及学术机构、政府机构和基金会进行。
区域展望
按地区划分,对北美、欧洲、亚太地区和拉美地区的心臟安全装置进行了分析。北美地区将在 2021 年占据心臟安全服务市场的最高收入份额。这是由于该地区的临床研究数量不断增加以及对心臟安全服务的需求不断增加。越来越多的心血管疾病 (CVD) 和冠心病 (CHD) 患者正在加速该地区的药物开发和研究。
收购是市场进入者采取的主要策略。根据 Cardinal 矩阵中的分析,Pharmaceutical Product Development, Inc. 是心臟安全服务市场的领先先驱。 Koninklijke Philips N.V.、Laboratory Corporation of America Holdings 和 IQVIA Holdings, Inc. 等公司是心臟安全服务市场的领先创新者。
The Global Cardiac Safety Services Market size is expected to reach $1.1 billion by 2028, rising at a market growth of 11.1% CAGR during the forecast period.
Cardiac safety services assist and design clinical studies & trials and other research necessary for the monitoring of heart safety. These are primarily concerned with tracking the full cardiac safety profile through all clinical trial phases, from Phase I through Phase IV. Guidelines and regulations given by most major and recognized medical authorities of various countries and other regulating agencies are followed while developing cardiac safety clinical trials and studies.
These services include physiologic stress testing, non-invasive cardiac imaging, platelet aggregation, ambulatory blood pressure monitoring, and other services in addition to the QT tests. Due to the grouping of services with an emphasis on end-to-end development, integrated services that provide cardiac safety services are generally favored over standalone services because of the peculiarity of standalone services.
All elements of the cardiovascular system, including the heart, blood vessels, and blood constituents, are affected by cardiovascular safety liabilities, which include both cardiovascular and non-cardiovascular pharmaceuticals. Cardiovascular adverse effects can be functional or structural (such as histopathology) in nature and can happen after acute or chronic treatment.
The need for effective yet secure drug development is more critical than ever in a time of growing public scrutiny, rising business expenses, and limited resources at regulatory agencies. With 17.9 million deaths per year, cardiovascular diseases (CVDs) are the most common cause of death worldwide. Cerebrovascular disease, coronary heart disease, rheumatic heart disease, and other illnesses are among the category of heart and blood vessel disorders known as CVDs.
COVID-19 Impact Analysis
This prompted the pharmaceutical and health insurance industries to make the necessary changes to their offerings in order to include better provisions and facilities. In order to progress the evolution of medicine, this compelled the engagement of numerous research institutions and organizations dedicated to heart health. Coronavirus-related catastrophes caused a significant number of patients with pre-existing unfavorable disorders to succumb to them, which had an effect on cardiac safety services. As a result of COVID-19's vigorous promotion of its development, the market for cardiac safety services was positively affected overall.
Market Growth Factors
Increase In Research For Biosimilars And Biologics
Numerous businesses are making significant investments in the creation of biologics and biosimilar compounds. In the discovery stage, biologics such peptides, proteins, and monoclonal antibodies make up more than half of the therapeutic candidates. Pharmaceutical and biopharmaceutical businesses are heavily putting money into their research and development as novel biologics are being developed or are in the pipeline. Biosimilars are also less expensive because, being generic versions of patented biologic medications, they are not subject to the same strict regulatory standards.
High Prevalence Of Ech Holter Service Among The General Population
The rise in the number of elderly people and the increasing incidence of cardiovascular disorders are mostly to blame for the ECG Holter's expansion. According to data released by Health System Tracker, heart disease is the top cause of mortality in the United States. These reasons make immediate heartbeat detection and constant heart rate monitoring equipment necessary. In the past few years, the healthcare system has employed ECG monitoring devices to look for any abnormalities in cardiac activity.
Market Restraining Factors
Lack Of Qualified Personnel For Clinical Trials
The R&D outsourcing industry for pharmaceuticals, biotechnology, and medical devices is always changing. To deliver high-quality services, adhere to acceptable laboratory procedures, and keep up with the ongoing developments in medical device and pharmaceutical R&D technologies and techniques, highly skilled experts are needed. As they compete for trained and experienced scientists with biotechnology, pharmaceutical, and medical device businesses as well as research and academic organizations, CROs confront difficulties in attracting and keeping highly skilled personnel.
Type Outlook
Based on type, the cardiac safety services market is bifurcated into integrated and standalone. The integrated segment dominated the cardiac safety services market with the highest revenue share in 2021. These cutting-edge core lab services provide a full range of cardiac safety services, including imaging, TQT, and profile QT tests. In order to help with the real-time evaluation of heart rate and rhythm, they also keep an eye on off-target cardiovascular liabilities and conduct onsite multichannel telemetry under the supervision of licensed nurses.
Type of Service Outlook
On the basis of type of service, the cardiac safety services market is divided into ECG/Holter measurement, blood pressure measurement, cardiovascular imaging, thorough QT studies, and other services. The ECG/Holter measurement segment witnessed the largest revenue share in the cardiac safety services market in 2021. Smartwatches and other personal electronics provide electrocardiogram monitoring. A small, portable gadget called a Holter monitor is used to capture heartbeats. It is employed to identify and evaluate the likelihood of aberrant heartbeats (arrhythmias).
End User Outlook
Based on end user, the cardiac safety services market is categorized into pharmaceutical & biopharmaceutical companies and contract research organizations. The contract research organizations segment procured a substantial revenue share in the cardiac safety services market in 2021. Clinical trials are carried out by Contract Research Organizations (CROs) for the pharmaceutical, medical device, and biotechnology businesses as well as for academic institutions, governmental agencies, and foundations.
Regional Outlook
On the basis of region, the cardiac safety devices is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region acquired the highest revenue share in the cardiac safety services market in 2021. This is due to the region's growing number of clinical studies, which are fueling demands for cardiac safety services. The rising number of people suffering from cardiovascular diseases (CVD) and coronary heart disease (CHD) have accelerated the drug development and research studies in the region.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; Pharmaceutical Product Development, Inc. is the major forerunner in the Cardiac Safety Services Market. Companies such as Koninklijke Philips N.V., Laboratory Corporation of America Holdings, IQVIA Holdings, Inc. are some of the key innovators in Cardiac Safety Services Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Clario, IQVIA Holdings, Inc., Laboratory Corporation of America Holdings, Pharmaceutical Product Development, Inc., SGS S.A., Banook Group, Biotrial Research SAS, Certara, Inc., and Celerion.
Strategies deployed in Cardiac Safety Services Market
Aug-2022: Labcorp acquired RWJBarnabas Health, a network of independent healthcare providers in New Jersey. Through this acquisition, Labcorp planned to offer expanded health plan coverage, enhanced service to rural markets, and the potential for reduced out-of-pocket lab costs for patients.
Jun-2022: The Banook Group expanded its geographical footprint by opening its first US office in Boston, Massachusetts. Through this expansion, Banook aimed to reduce the constraints of time zones and to provide enhanced technical and logistics support to its customers as about 40% of Banook's customers are based in this region. The expansion also allowed the company to offer local support to its 70 current US customers and to grow in the North American market.
Apr-2022: Royal Philips, partnered with Prisma Health, South Carolina's largest non-profit healthcare system. Through this partnership, the companies agreed to help the health system achieve enterprise interoperability, standardize patient monitoring, and drive innovation in enterprise imaging solutions to enhance patient care and improve clinical performance.
Mar-2022: IQVIA unveiled OCE+, the first of several new advancements to its leading life science customer engagement platform. OCE+ adds IQVIA's Next Best recommendation engine to its Orchestrated Customer Engagement (OCE) platform, providing enhanced HCP experiences, improved productivity, and increased ROI. The product uses IQVIA's industry-leading data and advanced analytics to deliver AI-driven recommendations directly into the daily workflows of life sciences commercial teams.
Jan-2022: Clario partnered with ActiGraph, a pioneer and leading provider of activity-sensing wearable technology. From this partnership, Clario expanded its evidence generation platform and portfolio of decentralization technologies and offered ActiGraph technologies to its customers in addition to its suite of eCOA, Precision Motion, Cardiac Safety, Respiratory, Medical Imaging, and Trial Enablement solutions. The partnership also helped clinical trial sites and sponsors to drive up efficiency and accuracy while increasing convenience for study participants.
Dec-2021: Labcorp took over Personal Genome Diagnostics (PGDx), a provider of comprehensive liquid biopsy and tissue-based genomic products and services. From this acquisition, Labcorp aimed to strengthen its next-generation sequencing-based genomic profiling capabilities and accelerate the existing liquid biopsy capabilities.
Nov-2021: Royal Philips acquired Cardiologs, a French medical technology firm. From this acquisition, Royal Philips aimed at expanding its cardiac monitoring and diagnostics portfolio with innovative software technology, electrocardiogram (ECG) analysis, and reporting services.
Sep-2021: The Banook Group acquired Nabios, biotech with strong expertise in cardiac safety assessments in clinical trials of drugs intended for human health. Through this acquisition, the company advanced its steps towards becoming the leader in the cardiac safety market by offering a strong European alternative to those companies operating from North America or India. This acquisition also granted Banook's customers access to new and more competitive services.
Sep-2021: IQVIA collaborated with HealthCore, a leading real-world research organization in the United States. Under the collaboration, the companies focused on advancing real-world evidence (RWE) studies with increased quality and efficiency. The innovative research collaboration focused specifically on real-world studies such as external comparators, pragmatic trials, and enriched studies.
Mar-2021: Certara took over AUTHOR!, a provider of medical writing and statistical analysis of clinical trial data to global pharmaceutical and biotechnology companies. Through this acquisition, Certara enhanced the existing regulatory and biostatistical expertise and helped to fuel the company's strategic expansion in Europe. Additionally, from the acquisition, Certara leveraged AUTHOR!'s seasoned team to provide technology-enabled capabilities to its customers and thus help global clients expertly navigate and accelerate the drug development and regulatory approval process.
Feb-2021: Royal Philips took over BioTelemetry, a leading U.S.-based provider of remote cardiac diagnostics and monitoring. Through this acquisition, Royal Philips expanded its cardiac care portfolio, and its strategy to transform the delivery of care along the health continuum with integrated solutions.
Feb-2021: Philips formed a partnership with SAZ hospital network, a Dutch Hospital network comprising 28 hospitals. Under this partnership, Philips offered advanced patient monitoring and population health management solutions to the SAZ network hospitals. In addition, Philips solutions enabled SAZ to enhance monitoring, observation, and self-management of patients across the care journey, both inside and outside the hospitals.
Mar-2018: Certara introduced Quantitative Systems Pharmacology (QSP) Immuno-oncology Simulator Consortium. The product combines computational modeling and experimental methods to examine the mechanistic relationships between a drug, the biological system, and the disease process. In addition, QSP integrates quantitative drug data with the knowledge of the drug's mechanism of action.
Market Segments covered in the Report:
By Type
By End User
By Type of Service
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures